Anzeige
Mehr »
Donnerstag, 14.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0D9T1 | ISIN: US2521311074 | Ticker-Symbol: DC4
Tradegate
13.08.25 | 21:42
68,37 Euro
+0,04 % +0,03
1-Jahres-Chart
DEXCOM INC Chart 1 Jahr
5-Tage-Chart
DEXCOM INC 5-Tage-Chart
RealtimeGeldBriefZeit
68,5268,9413.08.
68,1668,5113.08.
ACCESS Newswire
245 Leser
Artikel bewerten:
(1)

FriskaAi and Dexcom Enter CGM Data Integration Agreement

ARLINGTON, VA / ACCESS Newswire / August 13, 2025 / FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems into the FriskaAi platform. Under the agreement, data from Dexcom CGMs will be integrated with Friska Ai, the company's groundbreaking AI-powered healthcare platform supporting physicians and patients with actionable personalized care management programs.

FriskaAi is a physician-directed health and wellness platform that supports the management of diabetes and other chronic diseases by helping providers take an evidence-based approach to preventive care. The EHR-agnostic FriskaAi platform leverages advanced AI and mobile technology to generate personalized health insights and recommendations, empowering patients to take control of their health journey in partnership with their clinical team.

"Impacting more than 38 million Americans, diabetes has emerged as a major public health problem, and its effective management has become a foundational element of preventive medicine," says Shaji Nair, CEO of FriskaAi. "Dexcom's pioneering CGMs are vital tools not only for diabetes management but also for informing broader care decisions. FriskaAi is excited about the potential this integration with Dexcom presents to the physicians relying on our platform for chronic disease management and the patients seeking greater control over their health and wellness."

Dexcom CGMs use a small, wearable sensor to continuously measure and send glucose levels wirelessly to a smart device or receiver in real-time, without the need for fingerpricks. Dexcom CGMs also offer a suite of customizable alerts that can warn of high or low glucose levels and send predictive alerts to help users spend more time in range.

The FriskaAi mobile app securely integrates with Dexcom CGMs and other smart devices, as well as health apps, for analysis by the powerful HIPAA-compliant FriskaAi platform. That data, along with other clinical data and studies, is continuously monitored by sophisticated AI-powered algorithms that alert the patient when action is recommended and generate actionable reports for use by the clinician at the point of care to inform care decisions.

Aggregated health data is also analyzed within the FriskaAI platform to help physicians identify trends and risks within their patient populations, enabling more proactive and preventive care strategies.

About FriskaAi

FriskaAi is a powerful AI-enabled EHR-agnostic platform that helps physicians and other providers take an evidence-based approach to preventive care. The physician-initiated platform leverages advanced AI- and mobile technology to provide patients with personalized health insights and recommendations, empowering them to take control of their health journey in partnership with their clinical team. This aggregated health data, including information from patients' glucometers, other smart devices, and health apps, is continuously analyzed by advanced evidence-based algorithms that alert the patient when action is needed and provide clinicians with actionable reports to inform care decisions. FriskaAi also supports population health strategies by analyzing aggregated health data to identify trends and risks within a defined patient population. For more information, visit www.friska.ai.

Media Contact:
Michele Nachum
NPC Creative Services
michele@npccs.com

SOURCE: FriskaAi



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/friskaai-and-dexcom-enter-cgm-data-integration-agreement-1060203

© 2025 ACCESS Newswire
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.